Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab

Exclusion Criteria

• •Any of the following prior therapy: Chemotherapy ≤ 3 weeks prior to registration. Biologic therapy ≤ 4 weeks prior to registration. Radiation therapy ≤ 3 weeks prior to registration
• •Other concurrent investigational therapy (utilized for a non-FDA-approved indication and in the context of a research investigation).
• •Pregnant women.
• •Nursing women.
• •Men or women of childbearing potential who are unwilling to employ adequate contraception during treatment and 8 weeks following the completion of study drug treatment.
• •Allergy to measles vaccine or history of severe reaction to prior measles vaccination.
• •History of organ transplantation.